XGN
EXAGEN INC.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$8.41
+6.86%Year over year
Reported trailing growth
- Revenue
- +20.8%
- EBITDA
- +7.5%
- EBIT
- +5.9%
- EPS
- +7.9%
- Free cash flow
- +52.5%
- Operating cash flow
- +57.7%
Forward estimates
Based on analyst estimates
- Revenue
- +7.8%
- EBITDA
- +29.9%
- EPS
- +21.1%
Three-year CAGR
- Revenue
- +13.5%
- EBITDA
- -20.8%
- EBIT
- -3.2%
- Net income
- -32.0%
- EPS
- -12.0%
- Free cash flow
- -3.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026